Hansoh Pharma reports near 36% rise in first-half profit
26/08/2026 10:37
Hansoh Pharma reports near 36% rise in first-half profit Aug 26 (Reuters) - China's Hansoh Pharmaceutical Group 3692.HK, a Roche ROPC.S partner, reported a near 36% rise in first half profit on Wednesday, driven by strong growth in sales of innovative medicines and higher investment income.
The oncology and metabolic disease specialist posted net profit attributable of 4.26 billion yuan ($633.90 million) for the six months ended June 30, as compared to a profit of 3.13 billion yuan a year ago.
($1 = 6.7203 Chinese yuan renminbi)
(Reporting by Roshan Thomas in Bengaluru and Andrew Silver in Shanghai; Editing by Ronojoy Mazumdar)
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion